Big Pharma giant Roche has quietly cut a series of early- to midstage experimental drugs as it continues the traditional quarterly clear-out.
Last night, Amgen and UCB Pharma announced that although their osteoporosis drug, romosozumab, prevented fractures of the vertebrae in post-menopausal women, it also may have increased the risk of heart attacks by 30%.
Merck & Co has decided to discontinue development of its osteoporosis candidate odanacatib after seeing an elevated risk of stroke in studies.
Market Place
Share
Odanacatib News Full Screen View
Share
